GENSIGHT BIOLOGICS SA (SIGHT.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:SIGHT - FR0013183985 - Common Stock
0.0828 EUR
+0 (+2.99%)
Overall SIGHT gets a fundamental rating of 1 out of 10. We evaluated SIGHT against 85 industry peers in the Biotechnology industry. Both the profitability and financial health of SIGHT have multiple concerns. SIGHT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- SIGHT had negative earnings in the past year.
- SIGHT had a negative operating cash flow in the past year.
- SIGHT had negative earnings in each of the past 5 years.
- SIGHT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- SIGHT has a worse Return On Assets (-205.69%) than 89.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -205.69% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-174.59%
ROA(5y)-129.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for SIGHT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- SIGHT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, SIGHT has more shares outstanding
- The number of shares outstanding for SIGHT has been increased compared to 5 years ago.
- SIGHT has a better debt/assets ratio than last year.
2.2 Solvency
- SIGHT has an Altman-Z score of -56.61. This is a bad value and indicates that SIGHT is not financially healthy and even has some risk of bankruptcy.
- SIGHT has a Altman-Z score of -56.61. This is amonst the worse of the industry: SIGHT underperforms 84.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -56.61 |
ROIC/WACCN/A
WACC4.84%
2.3 Liquidity
- A Current Ratio of 0.11 indicates that SIGHT may have some problems paying its short term obligations.
- Looking at the Current ratio, with a value of 0.11, SIGHT is doing worse than 94.12% of the companies in the same industry.
- A Quick Ratio of 0.11 indicates that SIGHT may have some problems paying its short term obligations.
- SIGHT has a worse Quick ratio (0.11) than 94.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.11 | ||
| Quick Ratio | 0.11 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 78.83% over the past year.
- Looking at the last year, SIGHT shows a very negative growth in Revenue. The Revenue has decreased by -91.76% in the last year.
- The Revenue has been growing by 16.47% on average over the past years. This is quite good.
EPS 1Y (TTM)78.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.2%
Revenue 1Y (TTM)-91.76%
Revenue growth 3Y-34.24%
Revenue growth 5Y16.47%
Sales Q2Q%-120.15%
3.2 Future
- SIGHT is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -27.07% yearly.
- The Revenue is expected to grow by 102.12% on average over the next years. This is a very strong growth
EPS Next Y-2.06%
EPS Next 2Y-35.46%
EPS Next 3Y-27.07%
EPS Next 5YN/A
Revenue Next Year29.37%
Revenue Next 2Y12.12%
Revenue Next 3Y102.12%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for SIGHT. In the last year negative earnings were reported.
- Also next year SIGHT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- SIGHT's earnings are expected to decrease with -27.07% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.46%
EPS Next 3Y-27.07%
5. Dividend
5.1 Amount
- SIGHT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
GENSIGHT BIOLOGICS SA / SIGHT.PA FAQ
What is the fundamental rating for SIGHT stock?
ChartMill assigns a fundamental rating of 1 / 10 to SIGHT.PA.
What is the valuation status of GENSIGHT BIOLOGICS SA (SIGHT.PA) stock?
ChartMill assigns a valuation rating of 0 / 10 to GENSIGHT BIOLOGICS SA (SIGHT.PA). This can be considered as Overvalued.
How profitable is GENSIGHT BIOLOGICS SA (SIGHT.PA) stock?
GENSIGHT BIOLOGICS SA (SIGHT.PA) has a profitability rating of 0 / 10.
Can you provide the financial health for SIGHT stock?
The financial health rating of GENSIGHT BIOLOGICS SA (SIGHT.PA) is 0 / 10.
What is the earnings growth outlook for GENSIGHT BIOLOGICS SA?
The Earnings per Share (EPS) of GENSIGHT BIOLOGICS SA (SIGHT.PA) is expected to decline by -2.06% in the next year.